Navigation Links
Hypertension treatment effective in reversing vascular damage
Date:6/17/2008

WINSTON-SALEM, N.C. A hypertension medication called olmesartan medoxomil is effective in reversing the narrowing of the arteries that occurs in patients with high blood pressure, according to a new study.

Carlos M. Ferrario, M.D., one of the study's lead investigators and director of the Hypertension and Vascular Research Center at Wake Forest University Baptist Medical Center, said, "We believe the data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process."

The one-year study, titled Vascular Improvement with Olmesartan medoxomil Study (VIOS), was published in the current Journal of the American Society of Hypertension. The study evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with stage 1 hypertension.

Olmesartan medoxomil is marketed in the United States as Benicar and in Europe as Olmetec by Daiichi Sankyo, Inc., which funded the study.

After one year of treatment, olmesartan medoxomil improved the artery abnormalities in high blood pressure patients and returned arterial architecture to normal levels. This was not seen with the atenolol.

Olmesartan medoxomil is a member of a class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels that causes constriction and increase blood pressure. This medication also blocks the release of a hormone that causes salt retention and increased blood volume.

Hypertension affects one in three Americans and, if left uncontrolled for a long time, can cause organ damage, as well as heart disease, stroke and other problems.

Olmesartan is currently being reviewed in several trials, including the Randomized Olmesartan and Diabetes Microalbuminuria Prevention study (ROADMAP), which is investigating the drug's effectiveness in preventing early stage kidney disease in 4,400 patients with type 2 diabetes.

The VIOS results were presented at the Hypertension 2008 symposium, a scientific conference co-hosted by the European and International Societies of Hypertension. Dr. Ferrario was in Berlin, Germany, for the symposium, where he conducted interviews on Sunday and yesterday with international media about the significance of the VIOS data.


'/>"/>

Contact: Ann Hopkins
ahopkins@wfubmc.edu
336-716-1280
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related biology news :

1. Rare genetic mutations protect against hypertension
2. Researchers discovery may lead to hypertension treatment
3. Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
4. Understanding hypertension in African Americans proves elusive
5. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
6. Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment
7. Novel therapeutic strategy for colon cancer treatment
8. New ballast treatment could protect Great Lakes fish
9. Quest for better treatment for effects of menopause
10. Sugar linkage could lead to better treatment for autoimmune diseases
11. Glypican-3 gene function in regulating body size helps inform novel cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... on health-related quality of life, today announced its full advisory board. The board ... announced the promotion of James Crooks, PhD, former VP of Engineering, to Chief ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corporate Directors Forum is recognizing six San Diego ... the Year Awards. , The awards will be presented Thursday, September 7th, from 6 ... directors who have made significantly positive contributions in the boardrooms of some of our ...
(Date:7/18/2017)... Switzerland (PRWEB) , ... July 18, 2017 , ... ... R&D, today announced that Merck, a leading science and technology company, has implemented ... innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , ...
(Date:7/18/2017)... ... 18, 2017 , ... Recently recognized by CIO Magazine as ... migration of its flagship cloud-based product Planet Life Cycle – a robust work ... system that merges strategic and financial planning with execution. The solution is leveraged ...
Breaking Biology Technology: